{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04623606",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CMCB2B0X"
      },
      "Organization": {
        "OrgFullName": "Christian Medical College, Vellore, India",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones",
      "OfficialTitle": "Exploratory, Open Label, Multiple Dose, Phase I/II Trial Evaluating Safety, Efficacy of Intravenous and Intraosseous Infusion of Allogeneic Fetal Mesenchymal Stem In Treatment of Severe Osteogenesis Imperfecta Compared With Historical and Untreated Prospective Controls",
      "Acronym": "BOOST2B"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 20, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "November 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 18, 2020",
      "StudyFirstSubmitQCDate": "November 6, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 10, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 6, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 10, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Vrisha Madhuri",
        "ResponsiblePartyInvestigatorTitle": "Professor",
        "ResponsiblePartyInvestigatorAffiliation": "Christian Medical College, Vellore, India"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Christian Medical College, Vellore, India",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Ministry of Science and Technology, India",
            "CollaboratorClass": "OTHER_GOV"
          },
          {
            "CollaboratorName": "Vinnova",
            "CollaboratorClass": "OTHER_GOV"
          },
          {
            "CollaboratorName": "Karolinska Institutet",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "An exploratory, open label, multiple dose, phase I/II trial (n=15) evaluating safety and efficacy of intravenous and intraosseous infusion of allogeneic expanded fetal mesenchymal stem cells (MSC) for the treatment of severe Osteogenesis Imperfecta (OI) compared with historical and untreated prospective controls."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Osteogenesis Imperfecta"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "OI, Brittle bone disease",
          "Hereditary bone fragility"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Historical and Untreated prospective control and Treatment group",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Prospective Control (Untreated) and historical controls",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database"
          },
          {
            "ArmGroupLabel": "Treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: BOOST cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "BOOST cells",
            "InterventionDescription": "Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)",
            "PrimaryOutcomeDescription": "The primary endpoint is safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)/Serious AE (SAE)/Suspected Unexpected Serious Adverse Reaction (SUSAR)with specific focus on the following:\n\nVital signs in conjunction with the MSC infusion\nTransfusion reactions (infusion toxicity, embolism, allergy, infections)\nImmune reaction towards the cells, donor-specific antibodies, graft rejection, Graft versus Host Disease, autoimmunity)\nTumourigenicity\nMortality/morbidity",
            "PrimaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of fractures [ Time Frame: From baseline to 16 months follow-up ]",
            "SecondaryOutcomeDescription": "Number of fractures.",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.",
            "SecondaryOutcomeDescription": "Time (days) to first fracture after each stem cell administration. Number of fractures",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)",
            "SecondaryOutcomeDescription": "Change in bone-marrow density (g/cm2).",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Growth (cm). [ Time Frame: From baseline to16 months follow up]",
            "SecondaryOutcomeDescription": "Growth (cm) as assessed by clinician",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Weight (kg). [ Time Frame: From baseline to 16 months follow up]",
            "SecondaryOutcomeDescription": "Growth (kg) as assessed by clinician.",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]",
            "SecondaryOutcomeDescription": "Change in clinical status of OI based on parameters defined under efficacy assessments described in protocol, as assessed by OI clinician.",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker P-Calcium (mg %)",
            "SecondaryOutcomeTimeFrame": "From at baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker P-Phosphate (mg %)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker P-Albumin (g/dL)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker S-ALP (IU/L)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker S-CTx (mg %)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker fP-PTH (pg/mL)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker Vitamin D (nmol/L)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (μg/L) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker Bone specific S-ALP (μg/L)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker S-Osteocalcin (ng/mL)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples.",
            "SecondaryOutcomeDescription": "Assessment of biochemical bone turnover marker U-DPD/Krea and U-NTx/Krea (mg %)",
            "SecondaryOutcomeTimeFrame": "From baseline to 16 months follow up"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Impact on the subjects Quality of Life: Pediatric Quality of Life Questionnaire™ (PedsQOL) [ Time Frame: From baseline to the 16 month follow-up",
            "OtherOutcomeDescription": "Quality of life assessed using the Infant Pediatric Quality of Life Questionnaire™ (PedsQOL).",
            "OtherOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "OtherOutcomeMeasure": "Incidence of donor cells engrafted into patient tissue samples assessed by histology. [ Time Frame: From baseline to the 16 month follow up",
            "OtherOutcomeDescription": "Donor cell engraftment.",
            "OtherOutcomeTimeFrame": "From baseline to 16 months follow up"
          },
          {
            "OtherOutcomeMeasure": "Analysis of an array of cytokines and micro vesicles to evaluate paracrine effects. [ Time Frame: From baseline to the 16 month follow up",
            "OtherOutcomeDescription": "Paracrine effects will be analysed from plasma isolated from peripheral blood.",
            "OtherOutcomeTimeFrame": "From baseline to 16 months follow up"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "(i)Inclusion Criteria Treatment group\n\nParent's/legal guardian's signed informed-consent form\nClinical diagnosis of OI type III or IV AND\nMolecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene)\nAge between 1 to 4 years\nBP treatment initiated before inclusion\nParent/legal guardian over 18 years of age\n\n(ii)Inclusion Criteria Prospective Untreated Control Group and Historical Control Group:\n\nParent's/legal guardian's signed informed-consent form\nClinical and molecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene)\nAge between 4 to 8 years\nParent/legal guardian over 18 years of age\n\n(iii)Exclusion Criteria Treatment group Prospective and historical control group:\n\nExistence of other known disorder that might interfere with the treatment (such as severe malformations, congenital heart defect, hypoxic encephalopathy (l-lll), neurological problems, immune deficiencies, muscle diseases, syndromes) diagnosed by clinical examination\nAny contraindication for invasive procedures such as a moderate/severe bleeding tendency or contagious infections\nAbnormal karyotype or other confirmed genetic syndromes\nOncologic disease\nInability to comply with the trial protocol and evaluation and follow-up schedule\nInability to understand the information and to provide informed consent",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "1 Year",
      "MaximumAge": "8 Years",
      "StdAgeList": {
        "StdAge": [
          "Child"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Vrisha Madhuri, MS Orth",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "91-416-2282172",
            "CentralContactEMail": "madhuriwalter@cmcvellore.ac.in"
          },
          {
            "CentralContactName": "Suhasini Ganesh, M.Pharm",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "91-416-2285117",
            "CentralContactEMail": "brittlebonekids@cmcvellore.ac.in"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Vrisha Madhuri, MS Orth",
            "OverallOfficialAffiliation": "Christian Medical College, Vellore, India",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Christian Medical College",
            "LocationStatus": "Recruiting",
            "LocationCity": "Vellore",
            "LocationState": "Tamil Nadu",
            "LocationZip": "632004",
            "LocationCountry": "India",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Suhasini Ganesh, M.Pharm",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "91-416-2285117",
                  "LocationContactEMail": "brittlebonekids@cmcvellore.ac.in"
                },
                {
                  "LocationContactName": "Suhasini Ganesh, M Pharm",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "91-416-2285117",
                  "LocationContactEMail": "brittlebonekids@cmcvellore.ac.in"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Boost to Brittle Bones",
            "SeeAlsoLinkURL": "http://boost2b.in/"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010013",
            "ConditionMeshTerm": "Osteogenesis Imperfecta"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010009",
            "ConditionAncestorTerm": "Osteochondrodysplasias"
          },
          {
            "ConditionAncestorId": "D000001848",
            "ConditionAncestorTerm": "Bone Diseases, Developmental"
          },
          {
            "ConditionAncestorId": "D000001847",
            "ConditionAncestorTerm": "Bone Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          },
          {
            "ConditionAncestorId": "D000003095",
            "ConditionAncestorTerm": "Collagen Diseases"
          },
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12088",
            "ConditionBrowseLeafName": "Osteogenesis Imperfecta",
            "ConditionBrowseLeafAsFound": "Osteogenesis Imperfecta",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4278",
            "ConditionBrowseLeafName": "Bone Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12084",
            "ConditionBrowseLeafName": "Osteochondrodysplasias",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11195",
            "ConditionBrowseLeafName": "Mucopolysaccharidosis IV",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4279",
            "ConditionBrowseLeafName": "Bone Diseases, Developmental",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4306",
            "ConditionBrowseLeafName": "Osteogenesis Imperfecta",
            "ConditionBrowseLeafAsFound": "Osteogenesis Imperfecta",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T4309",
            "ConditionBrowseLeafName": "Osteogenesis Imperfecta Type III",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3909",
            "ConditionBrowseLeafName": "Mucopolysaccharidosis Type IV",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}